Skip to Main Content

Shalin Kothari, MD

Assistant Professor of Medicine (Hematology); Clinician Lead, Cancer Biology Training Program; Core Faculty, Medical Oncology and Hematology Fellowship Program

Contact Information

Shalin Kothari, MD

Research Summary

Dr. Kothari’s research is focused on using his clinical skills and basic science knowledge to answer scientific questions focused on mechanistic understanding of lymphoma therapeutics and its translation in the form of early-phase clinical trials for various aggressive forms of B-cell lymphomas including mantle cell lymphoma.

He is also an active member of the Müschen Laboratory here at Yale University and conducts laboratory experiments with a specific focus on developing new therapies for mantle cell lymphoma.


Research Interests

Drug Resistance; Apoptosis; Lymphoma, Mantle-Cell

Selected Publications

Clinical Trials

ConditionsStudy Title
Non-Hodgkin's LymphomaA Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)
Non-Hodgkin's LymphomaA Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Non-Hodgkin's LymphomaAn Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Hodgkin's Lymphoma; Lymphoid LeukemiaA Phase Ia/Ib Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, DTRM-505 and DTRM-555, in Patients With Chronic Lymphocytic Leukemia or Other B-cell Lymphomas
Non-Hodgkin's LymphomaPhase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell Lymphoma
Non-Hodgkin's LymphomaPhase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination With Anti-Neoplastic Agents in Subjects With Non-Hodgkin Lymphoma
Brain and Nervous System; Leukemia, not otherwise specified; Lymphoid Leukemia; Non-Hodgkin's LymphomaA Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies
Non-Hodgkin's LymphomaA Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy With Zanubrutinib as Upfront Treatment in Older Patients With Mantle Cell Lymphoma